Twist Bioscience (TWST) reported a fiscal Q4 loss Monday of $0.59 per diluted share, narrower than its loss of $0.81 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.70.

Revenue for the quarter ended Sept. 30 was $84.7 million, up from $66.9 million a year earlier.

Analysts surveyed by Capital IQ expected $82.7 million.

The company said it expects fiscal Q1 revenue of approximately $87 million. Analysts surveyed by Capital IQ expect $84.3 million.

For fiscal year 2025, the company expects revenue in a range between $367 million and $377 million. Analysts polled by Capital IQ expect $373.2 million.